Working… Menu

The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00436059
Recruitment Status : Completed
First Posted : February 16, 2007
Last Update Posted : July 8, 2009
Odense University Hospital
Information provided by:
Vejle Hospital

Brief Summary:
The primary objective of the the study is to investigate the changes in bone remodeling during Velcade treatment.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: bortezomib Phase 2

Detailed Description:

20 patients will be included in the study over a 2 year period. Before, during and after treatment we will measure NTX-I, CTX-I, CTX-MMP, bALP, DKK-1, PINP, TRAcP and PTH. NTX, CTX and CTX-MMP are measured to estimate bone degradation. TRAcP is measured to estimate the activity of the osteoclasts. bALP and DKK-1 is measured to evaluate the activity of the osteoblasts and PINP is measured as a marker of new bone formation. PTH is measured in order to evaluate if the positive effects that is observed in bone formation in relations to velcade treatment is due to the pulsative way velcade is administered.

The effect of the velcade treatment will be evaluated by x-ray, bone marrow and m-component.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)
Study Start Date : February 2007
Actual Primary Completion Date : July 2009
Actual Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
Drug Information available for: Bortezomib

Primary Outcome Measures :
  1. Changes in bone markers during treatment

Secondary Outcome Measures :
  1. Changes in osteolysis during treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Previously untreated multiple myeloma

Exclusion Criteria:

  • Use of bisfosfonates

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00436059

Layout table for location information
University Hospital Odense
Odense, Denmark, 5000
Vejle Hospital
Vejle, Denmark, 7100
Sponsors and Collaborators
Vejle Hospital
Odense University Hospital
Layout table for investigator information
Principal Investigator: Torben Plesner, MD Vejle Hospital

Layout table for additonal information Identifier: NCT00436059     History of Changes
Other Study ID Numbers: 2006/175
First Posted: February 16, 2007    Key Record Dates
Last Update Posted: July 8, 2009
Last Verified: July 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Bone Marrow Neoplasms
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Hematologic Neoplasms
Neoplasms by Site
Bone Marrow Diseases
Antineoplastic Agents